PT - JOURNAL ARTICLE AU - Erica Simons AU - Birgit Nikolay AU - Pascal Ouedraogo AU - Estelle Pasquier AU - Carlos Tiemeni AU - Ismael Adjaho AU - Colette Badjo AU - Kaouther Chamman AU - Mariam Diomandé AU - Mireille Dosso AU - Moussa Doumbia AU - Yves Asuni Izia AU - Hugues Kakompe AU - Anne Marie Katsomya AU - Vicky Kij AU - Viviane Kouakou Akissi AU - Christopher Mambula AU - Placide Mbala-Kingebeni AU - Jacques Muzinga AU - Basile Ngoy AU - Lou Penali AU - Alessandro Pini AU - Klaudia Porten AU - Halidou Salou AU - Daouda Sevede AU - Francisco Luquero AU - Etienne Gignoux TI - Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in two African settings: Lubumbashi, Democratic Republic of the Congo and Abidjan, Côte d’Ivoire AID - 10.1101/2022.12.12.22283387 DP - 2022 Jan 01 TA - medRxiv PG - 2022.12.12.22283387 4099 - http://medrxiv.org/content/early/2022/12/13/2022.12.12.22283387.short 4100 - http://medrxiv.org/content/early/2022/12/13/2022.12.12.22283387.full AB - Background Although seroprevalence studies have demonstrated the wide circulation of SARS-COV-2 in African countries, the impact on population health in these settings is still poorly understood. Using representative samples of the general population, we evaluated retrospective mortality and seroprevalence of anti-SARS-CoV-2 antibodies in Lubumbashi and Abidjan.Methods The studies included retrospective mortality surveys and nested anti-SARS-CoV-2 antibody prevalence surveys. In Lubumbashi the study took place during April-May 2021 and in Abidjan the survey was implemented in two phases: July-August 2021 and October-November 2021. Crude mortality rates were stratified between pre-pandemic and pandemic periods and further investigated by age group and COVID waves. Anti-SARS-CoV-2 seroprevalence was quantified by rapid diagnostic testing (RDT) and laboratory-based testing (ELISA in Lubumbashi and ECLIA in Abidjan).Results In Lubumbashi, the crude mortality rate (CMR) increased from 0.08 deaths per 10 000 persons per day (pre-pandemic) to 0.20 deaths per 10 000 persons per day (pandemic period). Increases were particularly pronounced among <5 years old. In Abidjan, no overall increase was observed during the pandemic period (pre-pandemic: 0.05 deaths per 10 000 persons per day; pandemic: 0.07 deaths per 10 000 persons per day). However, an increase was observed during the third wave (0.11 deaths per 10 000 persons per day). The estimated seroprevalence in Lubumbashi was 15.7% (RDT) and 43.2% (laboratory-based). In Abidjan, the estimated seroprevalence was 17.4% (RDT) and 72.9% (laboratory-based) during the first phase of the survey and 38.8% (RDT) and 82.2% (laboratory-based) during the second phase of the survey.Conclusion Although circulation of SARS-CoV-2 seems to have been extensive in both settings, the public health impact varied. The increases, particularly among the youngest age group, suggest indirect impacts of COVID and the pandemic on population health. The seroprevalence results confirmed substantial underdetection of cases through the national surveillance systems.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study in Lubumashi was funded by Médecins Sans Frontières - Operational Centre of Paris and the study in Abidjan by Médecins Sans Frontières - West and Central AfricaAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study in Lubumbashi has been approved by the Comité d'Etique Medicale of the University of Lubumbashi (ID UNILU/CEM/020/2020) and the study in Abidjan by the Comité National d'Etique des Sciences de la Vie et de la Sante (ID 054-21/MSHP/CNESVS-km). Both studies have been approved by the MSF ERB (ID 2089b, 2089d).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableThe minimal dataset underlying the findings of this study is available on request, in accordance with the legal framework set forth by Médecins Sans Frontières (MSF) data sharing policy (Karunakara U, PLoS Med 2013). MSF is committed to share and disseminate health data from its programs and research in an open, timely, and transparent manner in order to promote health benefits for populations while respecting ethical and legal obligations towards patients, research participants, and their communities. The MSF data sharing policy ensures that data will be available upon request to interested researchers while addressing all security, legal, and ethical concerns. All readers may contact data.sharing{at}msf.org or Nouha TOUATI (nouha.touati{at}epicentre.msf.org) to request data.